Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]
In development
Reference number: GID-TA11373
Expected publication date: TBC
Following its July meeting, the committee was unable to reach a full conclusion on givinostat because more information is needed. Consequently, NICE will not be issuing draft guidance for consultation at this stage. The committee has identified specific areas where additional evidence is required to support a fully informed decision. As a result, NICE has launched a four-week targeted call for evidence from stakeholders, ahead of a further committee meeting in October.